Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference19 articles.
1. Garrison LP Jr, Neumann PJ, Willke RJ, et al. A health economics approach to US value assessment frameworks: summary and recommendations of the ISPOR Special Task Force report [7]. Value Health. 2018;21:161–5.
2. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093–103.
3. Rand LZ, Kesselheim AS. Controversy over using quality-adjusted life-years in cost-effectiveness analyses: a systematic literature review. Health Aff (Millwood). 2021;40:1402–10.
4. Ubel PA, Nord E, Gold M, et al. Improving value measurement in cost-effectiveness analysis. Med Care. 2000;38:892–901.
5. National Council on Disability. Quality-adjusted life years and the devaluation of life with disability. Available from: https://ncd.gov/sites/default/files/NCD_Quality_Adjusted_Life_Report_508.pdf. Accessed 15 Apr 2023.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献